Medicines Shortages in the EU: The Impact, Cost, and Cause

Medicines shortages are no longer isolated or episodic events; they have become a structural challenge within the European pharmaceutical landscape. Over the past three years, reports from the European Medicines Agency (EMA) and various EU national health agencies have shown a steep rise in critical medicines shortages.

A 2024 report from the Pharmaceutical Group of the European Union (PGEU) showed that pharmacists across the EU spend more than one working day per week resolving medicine out-of-stock issues with their suppliers. PGEU found that most out-of-stocks were reported for antimicrobials, followed by painkillers, and then anaesthetics.

In approximately 89% of cases where an alternative was available, the product was replaced with a generic substitute.

The Impact on Patients and Industry

Ultimately, the patient is the stakeholder that suffers most. This limited access can delay treatment, require therapeutic substitution, or in some cases result in less optimal outcomes. Even where generics are available, switching products may create confusion, reduce adherence, or impact perceived treatment efficacy.

For pharmaceutical companies, loss of market share to generics can lead to significant financial and reputational consequences, including reduced revenue and patient confidence. Repeated supply disruptions can also affect relationships with regulators and payers, particularly in markets where continuity of supply is closely monitored.

Regulatory Obligations and Financial Exposure

The Marketing Authorisation Holder (MAH) of a medicinal product is required,¹ within the limits of their responsibility for the product, to ensure a robust and continuous supply of product to the patients to meet their needs.

Furthermore, each member state and EEA member has adopted widely varying rules to maintain a continuous supply of medicines. Some have mandated higher stockpiling levels in the local market, others impose fees or fines for out-of-stock reports, and all enforce penalties for failing to report a shortage within their required timeframe.

As demonstrated in Table 1, stockpiling requirements range from no formal minimum levels to several months of mandatory safety stock, depending on the country and product classification. Reporting timelines also differ, with some countries requiring notification months in advance of a potential stock shortage.

In some cases, late or non-reporting may lead to substantial financial penalties, with sums linked to product turnover.

Overall, the cost to a pharmaceutical company, financially in missed sales, regulatory fines, and lasting reputational damage, can escalate quickly. Depending on the member state, other sanctions may be imposed if the out-of-stock is the result of proven negligence on the part of the MAH.

¹ Per Article 81 of Directive 2001/83/EC.

Understanding the Root Causes

Medicine shortages are rarely due to a single failure but often arise from an accumulation of risk across manufacturing (GMP), distribution (GDP), supply chain, regulatory, and economic domains.

1. API Concentration and Globalisation

Many active pharmaceutical ingredients (APIs) are sourced from a limited number of global suppliers. Disruptions, such as quality failures, environmental events, or geopolitical instability, can lead to downstream impacts across multiple EU markets.

2. Recalls and Quality Events

High-risk medicine recalls can rapidly constrain supply, particularly where alternative sources are scarcely available.If manufacturing networks lack redundancy or secondary sourcing options, the withdrawal of a single batch or an entire product line may significantly disrupt supply.

3. Manufacturing Challenges (GMP-related)

Batch failures, out-of-specification results, and quality deviations can prevent finished product from reaching the market. In addition, overly optimistic production planning at contract manufacturing organisations may result in delays, particularly where capacity is constrained or multiple clients compete for limited manufacturing slots.

4. Distribution and Logistics Vulnerabilities (GDP-Related)

Extended distribution networks introduce additional risk. Loss or damage during transport, temperature excursions, customs delays, or poorly coordinated supply chain processes may reduce available stock before it reaches the intended market.

5. Parallel Importation

Parallel distribution exploits price differentials between Member States. Significant volumes may be redirected from lower-priced markets to higher-priced ones, occasionally pushing the exporting market below its intended safety stock threshold.

6. Regulatory Fragmentation

Divergent national stockpiling and reporting rules may inadvertently distort supply allocation. Suppliers facing stricter penalties in one jurisdiction may prioritise stock in that market, leaving others comparatively exposed.

Policy Developments: Toward Greater Harmonisation

PGEU, Medicines for Europe, and other steering groups have raised their concerns to EMA regarding the variability of national approaches. In March 2025, the European Commission proposed the Critical Medicines Act.

It aims to harmonise and improve the availability and supply of medicines through greater coordination, improved transparency of shortages, and potential harmonisation of stock requirements across Member States.

While policy reform may reduce fragmentation over time, implementation will require careful balancing of patient protection, market sustainability, and supply chain feasibility.

Ensuring Sustainable Supply

Managing medicine shortages requires more than reactive compliance with reporting obligations. It demands anintegrated, risk-based approach encompassing robust manufacturing oversight, diversified sourcing strategies, accurate demand forecasting, and regulatory intelligence across jurisdictions.

Early detection mechanisms and transparent communication with health authorities can mitigate both patient impact and financial exposure. At the same time, companies must carefully balance stock allocation across markets to avoid unintended supply distortions.

Medicines availability is fundamental to patient trust and public health stability. As regulatory expectations evolve and structural pressures persist, organisations that adopt forward-looking supply resilience strategies will be better positioned to ensure continuity of care across the European Union.